Big money: Flagship's uber-platform play Laronde rakes in $440M to chase programmable 'eRNA'
With the success of Moderna, parent company Flagship Pioneering has become the mothership for even more audacious next-gen platform plays. Investors like what they see, and now they’ve opened the vault to a particularly bold Flagship startup working on ring-shaped RNA it thinks could be the future of drugmaking.
Laronde has closed a $440 million Series B — one of the largest ever fundraising rounds of its type — to pursue a programmable RNA platform the biotech has previously said could churn out 100 marketed drugs or drug programs in 10 years.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,300+ biopharma pros reading Endpoints daily — and it's free.